Compare Citius Pharmaceuticals Inc (CTXR) vs National Beverage Corp. (FIZZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs National Beverage Corp. — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while National Beverage Corp. trades at $30.74 (market cap $2.89B). The key difference: National Beverage Corp. is far larger — about 212.2× Citius Pharmaceuticals Inc's market cap, and National Beverage Corp. is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and National Beverage Corp. for 33 Days on average.
| CTXR | FIZZ | |
|---|---|---|
Market Cap | $13.62M | $2.89B |
Volume | 132,438 | 553,950 |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $37.73 |
52-Week Low | $0.48 | $29.20 |
Typical Hold Time | 17 Days | 33 Days |
Enterprise Value | $3.79M | $2.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
National Beverage Corp. (FIZZ) trades at $30.36, up 2.57% today, showing mixed signals with a bullish technical outlook but bearish analyst sentiment. The stock faces margin pressure with recent earnings misses and declining revenue growth, though profitability metrics remain strong with 14.81% net margin and 40.13% ROE. Recent news highlights institutional buying and a $3.25 special dividend payment.
FIZZ presents a cautious investment case with strong profitability offset by growth challenges. The company's high ROE and solid margins provide fundamental support, but consecutive earnings misses and tariff-related margin compression create near-term headwinds. Analyst consensus leans bearish with 50% sell ratings, suggesting limited upside potential despite technical strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →
